两个品牌卡托普利治疗高血压成本效果分析.docVIP

两个品牌的卡托普利治疗高血压的成本-效果分析 　　[摘要] 目的：评价两个品牌的卡托普利治疗原发性高血压的经济效果。方法：83例轻、中度原发性高血压患者随机分成A、B两组，分别采用国产和合资生产两个品牌的卡托普利治疗8周，观察两组的疗效、不良反应，并进行成本-效果分析。结果：A、B两组的有效率分别为86.26%、86.35%，不良反应发生率分别为5.0%、4.7%，差异无统计学意义（P0.05）；药品成本分别为3.02元、750.60元，有显著性差异（P0.05），但药品成本有显著性差异（P0.01），国产卡托普利治疗高血压经济性较佳。 　　[关键词] 卡托普利；高血压；成本-效果分析 　　[中图分类号] R972+4[文献标识码]B[文章编号]1673-7210（2008）04（c）-041-02 　　 　　Cost-effectiveness analysis of Captopril of the two brandsfor treatment of hypertension 　　ZHANG Sheng-jie 　　(Changde Vocational Technical College, Changde 415000,China) 　　[Abstract] Objective:To evaluate the economic benefits of Captopril of the twobrands for treatment of hypertension.Methods: A total of 83 patients with hypertension were enrolled into 2 groups which were randomly assigned to receive Captopril of the two:group A to receive Captopril (made in China),and group B to receive Captopril(made in a Chinese-foreign joint venture). The medication duration was 8 weeks for all the 2 groups. The curative effects and adverse drug reactions of the 2 groups were monitored and evaluated by the cost-effectiveness analysis.Results:The tolal effective rates of groupA,B were 88.26%，86.35%, adverse drug reactions were 5% and 4.7%, respectively,showed no significant differences(P0.05);the cost of the 2 groups drug were 3.02 yuan, 750.6 yuan, respectively,showet significant difference in costs(P0.05).Conclusion: Group Ais more preferable than that of group B for treatment of hypertension in pharmacoeconomics. 　　[Key words] Hypertension;Captopril;Cost-effectiveness analysis 　　 　　高血压是一种常见的心血管疾病，我国患病率已达11%，严重威胁着人类的健康。高血压的有效治疗仍然是用降压药物来控制血压，目标血压138/83 mmHg，需要终生治疗，患者所需费用高。选择安全、有效、经济和适当的药物治疗，对减轻患者的经济负担，增加患者用药的依从性具有重要的现实意义。本文通过对两个品牌的卡托普利治疗轻、中度原发性高血压的成本-效果分析，为高血压患者合理选择药品提供参考；倡导使用药物经济性最佳的药物。 　　1资料与方法 　　1.1病例选择 　　按WHO制定的高血压诊断标准，选取门诊就诊轻、中度原发性高血压患者96 例。剔除伴有严重心、脑、肾并发症和继发性高血压患者，入选病例83 例，按随机化原则分为A（40例）和B（43例）两组。两组在性别、年龄、病程等方面差异均无显著性（P0.05）。见表1。 　　 　　两组患者性别、年龄、病程和用药前血压差异经χ2或t检验均无显著性（P0.05），具有可比性。 　　1.2 治疗方案 　　A组：卡托普利（